Jiang Lanlan, Yong Xiangzhi, Li Runying, Peng Yuanyuan, Liu Wei, Qin Qi, Zhang Linlin, Liu Zhenmin, Liang Hao, Tao Renchuan
Department of Periodontics and Oral Medicine, College of Stomatology, Guangxi Medical University, Guangxi, China; Guangxi Key Laboratory of AIDS Prevention and Treatment, Guangxi Medical University, Guangxi, China.
J Oral Pathol Med. 2014 Oct;43(9):696-703. doi: 10.1111/jop.12192. Epub 2014 Jun 14.
Highly active antiretroviral therapy (HAART) as an effective therapy for immune reconstruction among patients with HIV/AIDS might have influence on oral Candida status. We investigated oral Candida carriage, distribution, and antifungal susceptibility dynamically during the first year of HAART among adult HIV-infected patients in Guangxi, China.
Forty-five adult HIV-infected patients who received their first year HAART in the AIDS clinic of the Guangxi Center for Disease Control (CDC) and 31 healthy individuals were recruited. Clinical information and oral examinations were obtained. Oral rinses taken from patients at baseline, 3, 6, 12 months during HAART, respectively, were cultured, and Candida species were identified following standard microbiological techniques. In vitro antifungal susceptibilities were tested by the broth microdilution method.
The oral Candida load decreased gradually in the 45 patients with HIV/AIDS during the first year of HAART (P < 0.050). Among 176 Candida isolates, Candida albicans (114/176) was the predominant species, and Candida parapsilosis (23/62) was the most common non-albicans species. We found the frequency of resistance to fluconazole and itraconazole of Candida isolated from our samples increased (P < 0.05) after 12 months of HAART. In addition, the frequency of C. albicans isolates resistant to fluconazole and itraconazole was on the rise (P < 0.05).
The Candida load decreased with increased CD4(+) T cell counts, and C. albicans was still the prevailing species. Further, a trend toward more frequent in vitro resistance to fluconazole and itraconazole was observed. Our results provide reference for treatment and prevention of oral candidiasis among this population.
高效抗逆转录病毒疗法(HAART)作为治疗HIV/AIDS患者免疫重建的有效疗法,可能会对口腔念珠菌状况产生影响。我们对中国广西成年HIV感染患者接受HAART治疗的第一年期间的口腔念珠菌携带情况、分布及抗真菌药敏性进行了动态研究。
招募了45名在广西疾病预防控制中心(CDC)艾滋病门诊接受第一年HAART治疗的成年HIV感染患者和31名健康个体。获取了临床信息并进行了口腔检查。分别采集患者在HAART治疗基线期、3个月、6个月、12个月时的口腔冲洗液进行培养,并按照标准微生物技术鉴定念珠菌种类。采用肉汤微量稀释法检测体外抗真菌药敏性。
45例HIV/AIDS患者在HAART治疗的第一年期间口腔念珠菌载量逐渐下降(P < 0.050)。在176株念珠菌分离株中,白色念珠菌(114/176)是主要菌种,近平滑念珠菌(23/62)是最常见的非白色念珠菌菌种。我们发现,HAART治疗12个月后,从我们的样本中分离出的念珠菌对氟康唑和伊曲康唑的耐药频率增加(P < 0.05)。此外,白色念珠菌分离株对氟康唑和伊曲康唑的耐药频率呈上升趋势(P < 0.05)。
念珠菌载量随CD4(+) T细胞计数增加而下降,白色念珠菌仍是优势菌种。此外,观察到体外对氟康唑和伊曲康唑耐药的频率有增加趋势。我们的结果为该人群口腔念珠菌病的治疗和预防提供了参考。